April 18th 2024
Drs Lunning and Rutherford discuss findings from the ECHELON-1 trial of BV-AVD in the cohort of patients with Hodgkin lymphoma over 60 years of age.
March 18th 2024
Dr Lunning sits down with Alex Herrera, MD, to discuss the frontline management of Hodgkin lymphoma, including the SWOG 1826 trial.
October 12th 2023
Matthew Lunning, DO, FACP, discusses considerations for community oncologists who treat patients with relapsed/refractory follicular lymphoma.
March 2nd 2023
A panel of experts discuss the future of R/R DLBCL treatment and review some recent data from the 2022 ASH meeting.
Experts discuss the potential use of CAR T-cell therapy in the front line setting as well as reviewing the use of tafasitamab from the FRONT-MIND and FIRST-MIND trials.
February 22nd 2023
Insightful discussion among a panel of oncologists on how to best sequence therapies for patients with R/R DLBCL.
Experts review some of the safety outcomes from the ZUMA-7 trial as well as discussing the clinical implications of the ZUMA-7 trial into their practice.
February 15th 2023
An overview of the ZUMA-7 and the TRANSFORM trial as well as reviewing eligibility criteria for patients who might receive CAR-T therapy.
Panel of experts discuss where CAR T-cell therapy might fit into the treatment landscape for patients with R/R DLBCL.
February 8th 2023
Comprehensive insight into the L-MIND trial including a review of efficacy outcomes as well as discussing the implications of the data into clinical practice.
Experts discuss which factors are considered when choosing treatment options for patients with R/R DLBCL as well as reviewing the mechanism of tafasitamab.
February 1st 2023
Insightful discussion among experts into a brief overview of relapsed/refractory DLBCL (R/R DLBCL).
Expert oncologists provide a brief overview of front-line treatment options for patients diagnosed with double large b-cell lymphoma (DLBCL).